Beneficial effects of 1,3–1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation

• Published in: Journal of diabetes and metabolic disorders Vol. 22; no. 1; pp. 487 - 494
• Main Authors: Ikewaki, Nobunao, Ikeue, Yasunori, Nagataki, Mitsuru, Kurosawa, Gene, Dedeepiya, Vidyasagar Devaprasad, Rajmohan, Mathaiyan, Vaddi, Suryaprakash, Senthilkumar, Rajappa, Preethy, Senthilkumar, Abraham, Samuel J. K.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2023; Nature Publishing Group
• Subjects: Diabetes; Endocrinology; Fatty liver; Medicine; Medicine & Public Health; Metabolic Diseases; Metabolism; Research Article; Beta-Glucans; Nonesterified; Metabolic diseases; Dyslipidemias; Aureobasidium pullulans; Fatty acids
• ISSN: 2251-6581; 2251-6581
• DOI: 10.1007/s40200-022-01170-5

Objectives In this study, we used an obese and diabetic mouse model to compare two strains of Aureobasidium pullulans (AFO-202 and N-163) produced beta-glucans (β-glucans), which alleviate lipotoxicity. Methods Four groups of KK-Ay mice were used, with six subjects in each group. Group 1: sacrificed on day 0 for baseline values; Group 2: control (drinking water); Group 3: AFO-202 beta glucan—200 mg/kg/day; Group 4: N-163 beta glucan—300 mg/kg/day for 28 consecutive days. Results Group 4 (N-163) had the lowest non-esterified fatty acids (NEFA) levels and marginally decreased triglyceride levels compared to the other groups. There were no significant differences in blood glucose, hemoglobin A1c (HbA1c), triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels. N-163 β-glucans decreased NEFA levels after 28 days. Conclusion These results, although modest, warrant further in-depth research into lipotoxicity and associated inflammatory cascades in both healthy and diseased subjects for the prevention and management of metabolic dysregulation and associated diseases such as non-alcoholic fatty liver disease (NAFLD).